Fig. 1: Immunogenicity of VLA2001 in mice. | Communications Medicine

Fig. 1: Immunogenicity of VLA2001 in mice.

From: Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques

Fig. 1

Doses used for immunizations were from 0.3 to 3.0 arbitrary units (AU) (a–c, g) or 3.0 to 35 AU (d–f, h). Antibody titers were determined by ELISA using pooled sera from each group. Plates were coated with either S1 (a, d), RBD (b, e) or N-protein (c, f). Gray bars depict serum pools from mice immunized with VLA2001 formulated with alum and black bars show VLA2001 formulated with alum and CpG 1018™ adjuvant. Endpoint titers were determined using 3× the absorbance (405 nm) of the blanks as cut-off. The dotted lines refer to the limit of detection (LoD) 50, values below LoD were imputed with 25. g The IgG subclass responses (filled bars: IgG1, hatched bars: IgG2a) were determined using S protein specific mAbs with different IgG subclasses as references. h Pseudovirus neutralization assay was performed using MLV particles with SARS-CoV-2 S protein (614 G) and firefly luciferase as reporter. The dotted line depicts the LoD 20, values below LoD were imputed with 10.

Back to article page